TPC
LAB icon

Takeda Pharmaceutical Company’s Standard BioTools LAB Stock Holding History

Takeda Pharmaceutical Company’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$21.5K Hold
16,515
– – 0.13% 8
2025
Q2 		$19.8K Hold
16,515
– – 0.1% 11
2025
Q1 		$17.8K Hold
16,515
– – 0.11% 11
2024
Q4 		$28.9K Hold
16,515
– – 0.11% 11
2024
Q3 		$31.9K Hold
16,515
– – 0.08% 10
2024
Q2 		$29.2K Hold
16,515
– – 0.01% 13
2024
Q1 		$44.8K Hold
16,515
– – 0.02% 15
2023
Q4 		$36.5K Buy
+16,515
New +$35.3K 0.01% 14

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

Takeda Pharmaceutical Company's LAB Position: Q3 2025 in Review

Takeda Pharmaceutical Company held its Standard BioTools (LAB) position steady in Q3 2025 at 16,515 shares worth $21.5K. The position accounts for 0.13% of the portfolio, ranked #8.

Takeda Pharmaceutical Company first reported a position in LAB in Q4 2023 and has held it in 8 quarters since. The position peaked at $44.8K in Q1 2024. 155 funds tracked by Wall St. Rank hold LAB as of Q3 2025.

  • Takeda Pharmaceutical Company held 16,515 shares of Standard BioTools worth $21.5K as of Q3 2025.
  • Takeda Pharmaceutical Company left its Standard BioTools share count unchanged in Q3 2025.
  • Standard BioTools made up 0.13% of Takeda Pharmaceutical Company's portfolio in Q3 2025, its #8 holding.
  • Takeda Pharmaceutical Company first reported a position in Standard BioTools in Q4 2023 and has held it in 8 quarters since.
  • Takeda Pharmaceutical Company's Standard BioTools position peaked at $44.8K in Q1 2024.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2025.

Based on Takeda Pharmaceutical Company's 13F filing for Q3 2025, filed 13 Nov 2025.